Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action

MLA

Guntram Schernthaner, and Marie Helene Schernthaner-Reiter. “Combination Therapy of SGLT2 Inhibitors with Incretin-Based Therapies for the Treatment of Type 2 Diabetes Mellitus: Effects and Mechanisms of Action.” Expert Review of Endocrinologymetabolism, vol. 11, no. 3, July 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8b4f5f5265dea8df7fc1d9a518f22f10&authtype=sso&custid=ns315887.

APA

Guntram Schernthaner, & Marie Helene Schernthaner-Reiter. (2018). Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action. Expert Review of Endocrinologymetabolism, 11(3).

Chicago

Guntram Schernthaner, and Marie Helene Schernthaner-Reiter. 2018. “Combination Therapy of SGLT2 Inhibitors with Incretin-Based Therapies for the Treatment of Type 2 Diabetes Mellitus: Effects and Mechanisms of Action.” Expert Review of Endocrinologymetabolism 11 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8b4f5f5265dea8df7fc1d9a518f22f10&authtype=sso&custid=ns315887.